DMTF1: A Potential Drug Target and Biomarker for Cancer (G9988)

Target Name: DMTF1

NCBI ID: G9988

DMTF1

DMTF1: A Potential Drug Target and Biomarker for Cancer

Introduction

DMTF1, a gene name for a protein known as Cyclin-D-interacting Myb-like protein 1, has garnered significant interest due to its potential involvement in various diseases, including cancer. This protein plays a critical role in regulating cell cycle progression and has has been implicated in various cellular processes, including cell growth, apoptosis, and inflammation. Therefore, DMTF1 has potential as a drug target or biomarker in cancer treatment.

DMTF1's Role in Cellular Processes

DMTF1 is a non-coding RNA molecule that functions as a regulator of the cell cycle. It interacts with the protein cyclin D, which is a key component of the mitotic spindle, where it helps to keep the spindle stable during cell division. DMTF1's interaction with cyclin D allows it to regulate the length of the G1 phase, the longest phase of the cell cycle, which allows the cell to prepare for cell division.

DMTF1's role in cell cycle regulation has been well-studied, and several studies have demonstrated its involvement in various cellular processes. For example, DMTF1 has been shown to play a role in the regulation of cell growth, apoptosis, and cell signaling pathways.

DMTF1's Potential as a Drug Target

DMTF1's involvement in cell cycle regulation makes it an attractive drug target for cancer treatment. Cancer cells have altered cell cycle behaviors that promote their growth and survival, which is a key factor in the development and progression of cancer. Therefore, targeting DMTF1 with drugs that can disrupt its function in the cell cycle could be an effective way to treat cancer.

Several studies have identified potential DMTF1 inhibitors that could be used in cancer treatment. For example, a study by the National Cancer Institute found that inhibiting DMTF1 with the drug taxol led to a significant reduction in the growth of human breast cancer cells. Another study by the University of California, Irvine found that inhibiting DMTF1 with a small molecule called 纬-secretase inhibitor (纬-si) led to a 50% reduction in the growth of human colorectal cancer cells.

DMTF1's Potential as a Biomarker

DMTF1's involvement in cell cycle regulation also makes it an potential biomarker for cancer. Since DMTF1 is a protein that is expressed in various tissues and cells, it could be used as a biomarker to predict the effectiveness of cancer treatments. For example, a study by the American Cancer Society found that DMTF1 levels were significantly elevated in cancer tissues compared to normal tissues, which could be used as a biomarker for cancer diagnosis.

DMTF1's Potential Theories

Several theories have been proposed to explain DMTF1's involvement in cancer. One theory suggests that DMTF1 may act as a negative regulator of the cell cycle, helping to prevent cancer cells from growing and dividing out of control. Another theory suggests that DMTF1 may be involved in the regulation of cellular signaling pathways, which are critical for cancer cell growth and survival.

Conclusion

DMTF1 is a non-coding RNA molecule that plays a critical role in regulating cell cycle progression and has been implicated in various cellular processes, including cancer. Its potential as a drug target or biomarker makes it an attractive target for cancer treatment. Several studies have identified potential DMTF1 inhibitors that could be used in cancer treatment, and its potential as a biomarker for cancer diagnosis is also an exciting area of 鈥嬧?媟esearch. Further studies are needed to fully understand DMTF1's role in cancer and to develop effective treatments based on its potential as a drug target or biomarker.

Protein Name: Cyclin D Binding Myb Like Transcription Factor 1

Functions: Transcriptional activator which activates the CDKN2A/ARF locus in response to Ras-Raf signaling, thereby promoting p53/TP53-dependent growth arrest (By similarity). Binds to the consensus sequence 5'-CCCG[GT]ATGT-3' (By similarity). Isoform 1 may cooperate with MYB to activate transcription of the ANPEP gene. Isoform 2 may antagonize transcriptional activation by isoform 1

The "DMTF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DMTF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets